![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AbbVie Gains License Option to Cugene’s Autoimmune and Inflammatory Disease Portfolio
AbbVie Gains License Option to Cugene’s Autoimmune and Inflammatory Disease Portfolio
AbbVie has secured options to worldwide rights for several of Cugene’s interleukin-2 (IL-2) muteins, which are proteins with altered amino acid sequences that are being evaluated as potential treatments for autoimmune and inflammatory diseases.
Cugene’s lead candidate, CUG252, is designed to selectively activate immune-suppressive Treg cells while reducing undesired IL-2 activity. CUG252 is currently in a phase 1 study in healthy volunteers.
Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, plus additional payments for reaching developmental or regulatory milestones.
It will also receive separate payments if AbbVie exercises its licensing option for a particular mutein as well as sales-based milestones and tiered royalties.
Upcoming Events
-
21Oct